My watch list  


Systematic (IUPAC) name
3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
CAS number 105816-04-4
ATC code A10BX03
PubChem 60026
DrugBank APRD00593
Chemical data
Formula C19H27NO3 
Mol. mass 317.423 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 98%
Metabolism  ?
Half life 1.5 hours
Excretion  ?
Therapeutic considerations
Licence data


Pregnancy cat.


Legal status
Routes  ?

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.


Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.


Nateglinide is delivered in 60mg & 120mg tablet form.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nateglinide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE